摘要
对３６例住院慢性精神分裂症患者进行舒血宁治疗的双盲对照研究。患者随机分为舒血宁治疗组和安慰剂治疗组。舒血宁治疗组经八周治疗后其ＣＧＩ评分显著优于安慰剂治疗组（Ｐ＜０．０５）；其ＳＡＮＳ、ＳＡＮＳ五项总评及ＣＧＩ减分差（治疗前评分—治疗后评分）都显著优于安慰剂治疗组（分别为Ｐ＜０．０１～０．０５）。并观察不同剂量舒血宁的副反应。作者认为舒血宁与传统抗精神病药物合用，对治疗精神分裂症阴性症状有效。
Objective:To study the therapeutic effect of shuxuening (EGb761) in chronic schizophrenia.Method:This was a double-blind placebo controlled study. 36 patients with chronic schizophrenia were randomly divided into 2 groups and were given EGb761 and placebo for 8 weeks respectively.BPRS,SANS,CGI and TESS were used to evaluate therapeutic and side effects.Results:EGb761 was significantly superior to placebo according to CGI and SANS scores.No difference in side effect was found between the 2 groups at recommended dosage (EGb761 80mg tid).After finishing the 8-week trial,2 subjects were given an increased dosage of EGb761 (160mg tid) for another 2 weeks,but they developed new positive symptoms.Discussion:Within a specific dosage range,EGb761 is clinically effective for reducing the negative symptoms of schizophrenia.But it seems not to have effect on positive symptoms.Further studies of longer period of treatment are needed to address this issue.
出处
《临床精神医学杂志》
1996年第6期339-341,共3页
Journal of Clinical Psychiatry
关键词
慢性
精神分裂症
舒血宁
药物疗法
Chronic schizophrenia Negative symptoms Shuxuening(EGb761)
